| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(94)90064-7 |
| P698 | PubMed publication ID | 7909008 |
| P50 | author | JoAnn E. Manson | Q6204013 |
| Paul Ridker | Q7153226 | ||
| Meir J. Stampfer | Q80164992 | ||
| Charles H Hennekens | Q89527500 | ||
| P2093 | author name string | D E Vaughan | |
| P2860 | cites work | Final report on the aspirin component of the ongoing Physicians' Health Study | Q29619461 |
| Primary prevention of stroke | Q35250289 | ||
| Hematologic disorders and ischemic stroke. A selective review | Q37948687 | ||
| Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials | Q40813044 | ||
| Endogenous tissue-type plasminogen activator and risk of myocardial infarction | Q41079493 | ||
| Ischemic stroke due to deficiency of coagulation inhibitors. Report of 10 young adults | Q48365367 | ||
| High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. | Q51599999 | ||
| Fibrinogen and risk of cardiovascular disease. The Framingham Study. | Q52588834 | ||
| Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1) | Q69173266 | ||
| Hemostatic markers in acute stroke | Q69605424 | ||
| Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study | Q69886150 | ||
| Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction | Q69901572 | ||
| Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction | Q69973450 | ||
| Lipoprotein(a) as a strong indicator for cerebrovascular disease | Q70013947 | ||
| Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke | Q70401843 | ||
| ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography | Q70558786 | ||
| Fibrinogen as a risk factor for stroke and myocardial infarction | Q71438059 | ||
| Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study | Q72235431 | ||
| Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price | Q72873437 | ||
| P433 | issue | 8903 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | plasminogen | Q107129060 |
| P304 | page(s) | 940-943 | |
| P577 | publication date | 1994-04-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Prospective study of endogenous tissue plasminogen activator and risk of stroke | |
| P478 | volume | 343 |
| Q40401880 | A reliable marker of endothelial cell dysfunction: does it exist? |
| Q33922571 | A residential study comparing the effects of diets rich in stearic acid, oleic acid, and linoleic acid on fasting blood lipids, hemostatic variables and platelets in young healthy men. |
| Q34395534 | Alcohol consumption and risk of deep venous thrombosis and pulmonary embolism in older persons |
| Q90030308 | An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1 |
| Q46707808 | An Insertion/Deletion polymorphism in the promoter region of the plasminogen activator inhibitor-1 gene is associated with plasma levels but not with stroke risk in the elderly |
| Q38297868 | Angiotensin converting enzyme inhibitors--do they have an anti-ischemic action? |
| Q34239823 | Angiotensin, fibrinolysis, and vascular homeostasis |
| Q44411145 | Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients |
| Q35816401 | Are we content with lowering blood pressure alone, or should we be asking something more from the antihypertensive drugs we use?: effects of antihypertensive agents on fibrinolytic function. |
| Q28195472 | Aspirin resistance and genetic polymorphisms |
| Q46641204 | Association of the fibrinolytic system and hemorheology with symptoms in patients with carotid occlusive disease |
| Q52860018 | Associations between insulin resistance and thrombotic risk factors in high-risk South Asian subjects. |
| Q36030428 | Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice |
| Q37176377 | Cerebral small vessel disease: genetic risk assessment for prevention and treatment |
| Q37219105 | Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases |
| Q48666113 | Classic risk factors, hypercoagulability and migraine in young women with cerebral lacunar infarctions |
| Q59279108 | Complementary effects of Mediterranean diet and moderate red wine intake on haemostatic cardiovascular risk factors |
| Q54888331 | Decreased fibrinolytic potential in South Asian women with ischaemic cerebrovascular disease |
| Q42056700 | Earthquake-induced potentiation of acute risk factors in hypertensive elderly patients: possible triggering of cardiovascular events after a major earthquake |
| Q58823398 | Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease |
| Q47121555 | Effect of alcohol intoxication on the risk of venous thromboembolism: A nationwide retrospective cohort study. |
| Q43248763 | Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort s |
| Q35200997 | Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes |
| Q51544749 | Elevated plasma activator inhibitor 1 is not related to insulin resistance and to gene polymorphism in healthy centenarians. |
| Q34430443 | Endothelial dysfunction in the pathogenesis of atherosclerosis |
| Q71819548 | Enhanced Levels of Tissue-Type Plasminogen Activator in Borderline Hypertension |
| Q34065857 | Etiology and pathophysiology of stroke as a complex trait |
| Q90480618 | Fibrinogen concentrations predict long-term cognitive outcome in young ischemic stroke patients |
| Q35158979 | Fibrinolytic function and atrial fibrillation |
| Q34126048 | Fluvastatin: effects beyond cholesterol lowering |
| Q73681245 | Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease |
| Q73735151 | Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA |
| Q45884243 | Haemostasis balance disorders in patients with essential hypertension |
| Q36735179 | Haplotype Based Association Study between t-PA Gene and Essential Hypertension |
| Q37274431 | Hematological diseases and stroke |
| Q71874294 | Hemostatic Factors and the Risk of Myocardial Infarction |
| Q46665860 | Human gender differences in fibrinolytic responses to exercise training and their determinants |
| Q77643948 | Hypofibrinolysis in atrial fibrillation |
| Q44514165 | Increased Interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness |
| Q44019604 | Increased fibrinogen, von Willebrand factor and tissue plasminogen activator levels in insulin resistant South Asian patients with ischaemic stroke |
| Q73484494 | Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden |
| Q34025555 | Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation |
| Q74214766 | Interaction of fibrinolysis and prothrombotic risk factors in neonates, infants and children with and without thromboembolism and underlying cardiac disease. a prospective study |
| Q33919321 | Long-term prevention of ischaemic stroke and stroke recurrence |
| Q49039359 | Low serum BDNF may indicate the development of PSD in patients with acute ischemic stroke |
| Q62694077 | Markers of fibrinolytic potency and clotting activation in stable angina pectoris: role of urokinase, assessment of atrioventricular differences and correlation with coronary patency |
| Q34743382 | Obesity, haemostasis and the fibrinolytic system |
| Q52535925 | Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. |
| Q33740239 | Pathogenesis and pathology of coronary heart disease syndromes |
| Q71718204 | Pathophysiology of fibrinolysis |
| Q36986385 | Peculiarities of stroke risk in women. |
| Q35608208 | Pharmaceutical sponsorship bias influences thrombolytic literature in acute ischemic stroke |
| Q41047260 | Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events |
| Q73295877 | Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance |
| Q73295825 | Potential Antithrombotic and Fibrinolytic Properties of the Angiotensin Converting Enzyme Inhibitors |
| Q41440536 | Prevention of primary event. Ischemic stroke risk detection and reduction. |
| Q44351623 | Prevention of stroke |
| Q35774550 | Relation of C-reactive protein to endothelial fibrinolytic function in healthy adults. |
| Q73022835 | Risk factors and outcomes for atherothrombotic disease in French patients: the RIVAGE study. RIsque VAsculaire Group d'Etude |
| Q33709508 | Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies |
| Q36526467 | Self-reported habitual short sleep duration is associated with endothelial fibrinolytic dysfunction in men: a preliminary report. |
| Q34500682 | Stress, inflammation and cardiovascular disease |
| Q45155502 | Stroke, migraine, and headache |
| Q73157040 | Surgical stress induces acute coronary release of tissue-type plasminogen activator in the pig |
| Q34008359 | Testing for endothelial dysfunction |
| Q34551522 | The -7351C/T polymorphism in the TPA gene and ischemic stroke risk: a meta-analysis |
| Q77111391 | The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man |
| Q44343969 | The effect of 17 beta-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus |
| Q48182350 | The effect of age on expression of endogenous plasminogen activators after focal cerebral ischemia in mice |
| Q44010976 | The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis |
| Q35824621 | The metabolic syndrome: an emerging risk state for cardiovascular disease |
| Q31899830 | The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group |
| Q34557639 | The relationship between infection, inflammation, and cardiovascular disease: an overview |
| Q58282320 | The relationship between plasma androgens (dehydroepiandrosterone sulfate and testosterone), insulin, coagulation and fibrinolytic factors in men with coronary arteriosclerosis |
| Q36520556 | Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy |
| Q51735782 | Tissue plasminogen activator is elevated in women with ischemic stroke. |
| Q50532806 | [Improvement in fibrinolytic function following anticoagulant treatment in chronic rheumatic atrial fibrillation] |
Search more.